UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported): November 2, 2008
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
_____________________
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
1.01
|
ENTRY
INTO A MATERIAL DEFINITIVE
AGREEMENT.
|
On
November 2, 2008, Oramed Pharmaceuticals Inc. (the "Company") entered into
indemnification agreements with each of its directors and executive officers.
Under the indemnification agreements, the Company agrees to indemnify each
director and executive officer for any liability he or she may incur by reason
of the fact that he or she serves as the Company's director or executive
officer, to the maximum extent permitted by law.
This
form
of indemnification agreement is being furnished as Exhibit 10.1 to this Current
Report on Form 8-K and is incorporated herein by reference. The description
of
the indemnification agreement is qualified in its entirety by reference to
such
document.
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
10.1
|
Form
of Indemnification Agreement between Oramed Pharmaceuticals Inc.
and each
of its directors and executive
officers.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
ORAMED
PHARMACEUTICALS INC.
|
Dated:
November 6, 2008
|
|
|
|
|
|
By:
|
/s/
Nadav Kidron
|
|
|
|
Nadav
Kidron
|
|
|
|
President,
CEO and Director
|